The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

VolitionRx Q1 2026 Earnings Preview: Focus on Nu.Q Funding and Clinical Progress

Key Facts

1VolitionRx secured €2 million in non-dilutive funding from Belgian agencies to support its Nu.Q product portfolio.

2Analysts predict an EPS of -$0.04 and revenue of $753,575 for the Q1 2026 earnings report.

3Clinical studies highlighted the potential of Nu.Q biomarkers in trauma management and lung cancer.

Create Free Account

Version History

1 additional source confirmed this story

VolitionRx (VNRX) is set to release its Q1 2026 earnings report, with analysts projecting an earnings per share (EPS) loss of $0.04 on revenue of approximately $753,575. The company recently bolstered its financial position by securing €2 million in non-dilutive funding from Belgian agencies to support its Nu.Q product portfolio. Clinical developments remain a key focus for investors, as recent studies demonstrate the potential of Nu.Q biomarkers in managing trauma and detecting lung cancer. Despite these advancements and generating a gross profit, the company’s latest financial statement showed a net loss of $5.4 million. Markets are closely watching the transition of products to new IVDR regulatory standards and the validation of epigenetic blood tests through clinical trials. The combination of clinical progress and ongoing losses presents a mixed outlook for the biotech firm as it nears its next reporting date.